Helix BioPharma Corp. (TSE:HBP – Get Free Report) hit a new 52-week low during trading on Thursday . The stock traded as low as C$0.76 and last traded at C$0.82, with a volume of 7026 shares trading hands. The stock had previously closed at C$1.10.
Helix BioPharma Stock Down 4.9 %
The company has a debt-to-equity ratio of 773.67, a current ratio of 0.74 and a quick ratio of 1.04. The firm has a 50-day moving average of C$1.17 and a 200 day moving average of C$0.59. The stock has a market capitalization of C$38.24 million, a price-to-earnings ratio of -3.90 and a beta of -0.84.
Helix BioPharma Company Profile
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Featured Stories
- Five stocks we like better than Helix BioPharma
- Buy P&G Now, Before It Sets A New All-Time High
- Battle of the Retailers: Who Comes Out on Top?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
